New-onset atrial fibrillation after acute coronary syndrome: prevalence and predictive factors

##plugins.themes.academic_pro.article.sidebar##

Published Feb 4, 2022
Download
pdf
Vol. 100 No. 2 (2022): Issue feb 2022

##plugins.themes.academic_pro.article.main##

Manel Ben Halima
Wael Yaakoubi
Selim Boudiche
Bassem Rekik
Fathia Zghal Mghaieth
Sana Ouali
Mohamed Sami Mourali

Abstract

Introduction: New-onset AF atrial fibrillation (NOAF) frequently complicates acute coronary syndromes (ACS) leading to adverse
outcomes in the short and long term. The prevalence of NOAF in patients hospitalized for ACS is variably reported and ranges between 2
and 37%. Several predictor factors have been implicated in the literature but remain a subject of controversy.

Aim: To determine the prevalence of NOAF in a population of patients admitted for ACS and to identify its predictive factors.

Methods: We carried out a prospective, descriptive and comparative observational study in hospitalized patients with ACS who did not
have a previous diagnosis of AF.

Results: In our study, we included 404 patients hospitalized for ACS. The prevalence of NOAF was 10%. In the multivariate analytical
study, we retained as independent predictors of NOAF: age greater than 62 years (p = 0.04; adjusted OR = 4.83; CI95%: 1.07-21.77),
chronic renal failure (p = 0.043; adjusted OR = 6.61; CI95%: 1.06-35.80), history of stroke (p = 0.002; adjusted OR = 44.51; CI95%: 3.97-
498.10) and finally uricemia greater than or equal to 62 mg / l (p = 0.04; adjusted OR = 4.4; CI95%: 1.06-18.15).

Conclusions: The prevalence of NOAF in patients with ACS was 10%. Its systematic screening in these patients appears to be a relevant
approach because of the strong association between these two pathologies.

##plugins.themes.academic_pro.article.details##

References

  1. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, et al. A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23(15):1190‑201.
  2. Batra G, Svennblad B, Held C, Jernberg T, Johanson P, Wallentin L, et al. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart Br Card Soc 2016;102(12):926‑33.
  3. Wang J, Yang Y-M, Zhu J. Mechanisms of new-onset atrial fibrillation complicating acute coronary syndrome. Herz 2015;40(1):18‑26.
  4. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 2001;285(18):2370‑5.
  5. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22(8):983‑8.
  6. Eldar M, Canetti M, Rotstein Z, Boyko V, Gottlieb S, Kaplinsky E, et al. Significance of Paroxysmal Atrial Fibrillation Complicating Acute Myocardial Infarction in the Thrombolytic Era. Circulation 1998;97(10):965‑70.
  7. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39(2):119‑77.
  8. Thygesen K, Alpert JS., Jaffe AS., Chaitman R., Bax J., Morrow A., et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation 2018;138(20):e618‑51.
  9. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, et al. The TIMI risk score for unstable angina/ non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284(7):835‑42.
  10. Fox KAA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006;333(7578):1091.
  11. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003;163(19):2345‑53.
  12. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factorbased approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263‑72.
  13. Subherwal S, Bach RG, Chen AY, Gage BF, Rao SV, Newby LK, et al. Baseline risk of major bleeding in non-STsegment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 2009;119(14):1873‑82.
  14. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093‑100.
  15. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82
  16. Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 2000;140(6: 878‑85.
  17. Kinjo K, Sato H, Sato H, et al. Prognostic significance of atrial fibrillation/atrial flutter in patients with acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol 2003;92(10):1150‑4.
  18. Lin C-J, Liu C-F, Kung C-T, Sun C-K, Lin Y-C, Leu S, et al. The prognostic value of atrial fibrillation on 30-day clinical outcome in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Int Heart J 2011;52(3):153‑8.
  19. Congo KH, Belo A, Carvalho J, Neves D, Guerreiro R, Pais JA, et al. New-Onset Atrial Fibrillation in St-Segment Elevation Myocardial Infarction: Predictors and Impact on Therapy And Mortality. Arq Bras Cardiol 2019;113(5):948‑57.
  20. Thomsen P, Jons C, Raatikainen MJ. Long-term recording of cardiac arrhythmias with an implantable cardiac monitor in patients with reduced ejection fraction after acute myocardial infarction : the Cardiac Arrhythmias and Risk Stratification After Acute Myocardial Infarction (CARISMA) study. Circulation 2010;122(13) :1258-64
  21. Jons C, Raatikainen P, Gang UJ, Huikuri HV, Joergensen RM, Johannesen A, et al. Autonomic Dysfunction and New-Onset Atrial Fibrillation in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: A CARISMA Substudy. J Cardiovasc Electrophysiol 2010;21(9):983‑90.
  22. Yoshizaki T, Umetani K, Ino Y, Takahashi S, Nakamura M, Seto T, et al. Activated inflammation is related to the incidence of atrial fibrillation in patients with acute myocardial infarction. Intern Med Tokyo Jpn 2012;51(12):1467‑71.
  23. Wong C-K, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, et al. Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. Card Electrophysiol Rev 2003;7(3):201-7
  24. Rathore SS, Berger AK, Weinfurt KP, Schulman KA, Oetgen WJ, Gersh BJ, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation 2000;101(9):969‑74.
  25. Gorczyca-Michta I, Wożakowska-Kapłon B, Tomasik E. Prevalence and predisposing conditions for atrial fibrillation in hospitalised patients with hypertension. Kardiol Pol 2013;71(4):352‑8.
  26. Jin YY, Bai R, Ye M, Ai H, Zeng YJ, Nie SP. Risk factors and prognoses analysis of new-onset atrial fibrillation in patients with acute myocardial infarction . Zhonghua Nei Ke Za Zhi 2019;58(2):133‑8.
  27. 27 Mrdovic I, Savic L, Krljanac G, Perunicic J, Asanin M, Lasica R, et al. Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trial. Coron Artery Dis 2012;23(1):1‑8.
  28. Bahouth F, Mutlak D, Furman M, Musallam A, Hammerman H, Lessick J, et al. Relationship of functional mitral regurgitation to new-onset atrial fibrillation in acute myocardial infarction. Heart Br Card Soc 2010;96(9):683‑8.
  29. Stachon P, Ahrens I, Faber T et al. Asymptomatic atrial fibrillation and risk of stroke. Panminerva Med 2015;57(4):211-5.
  30. Karataş M, Çangaa Y, İpeka G. Association of admission serum laboratory parameters with new-onset atrial fibrillation after a primary percutaneous coronary intervention. Coronary Artery Disease 2016;27:128–134.
  31. Yildrim E, Ermis E, Allahverdiyev S et al. Value of syntax score II in Prediction of New-Onset Atrial Fibrillation in Patients with NSTE-ACS Undergoing Percutaneous Coronary intervention. Angiology 2019;70(9):860-866.
  32. Yoshizaki T, Umetani K, Ino Y, Takahashi S, Nakamura M, Seto T, et al. Activated inflammation is related to the incidence of atrial fibrillation in patients with acute myocardial infarction. Intern Med Tokyo Jpn